About this Research Topic
With their unprecedented success, cancer immunotherapies including immune checkpoint inhibitors (ICIs), cancer vaccines, adoptive cell therapy (ATC), and immunomodulators are being increasingly used for various malignancies. Distinct from traditional treatments including surgery, radiation therapy, and chemotherapy, immunotherapeutics attempt to create long-lasting anti-tumor effects. However, only a minority of patients experience long-term benefits to single-agent immunotherapy, and most patients do not have initial responses to the immunotherapy or develop relapse after promising initial responses. Strategies to overcome immunotherapy resistance include (1) the development of biomarkers to select potential responders and/or exclude potential non-responders; and (2) the usage of combination treatments (ICIs, radiotherapy, chemotherapy, vaccines, fecal microbiota transplantation (FMT) and etc.) comprising different mechanisms of action and target multiple resistant mechanisms. At the same time, the possibility of new side effects due to the combinatorial strategies or the potential amplification of the well-known side effects of the ICIs, termed immune-related adverse events (irAEs), should be carefully monitored.
The goal of this research topic is to broaden our knowledge from translational and basic research works that focus on approaches and ideas to enhance the target specificity of immunotherapeutic reagents and to reduce or prevent adverse events. This will also include the identification of biomarkers to predict responses as well as immunotoxicities.
This Research Topic aims to highlight the ongoing basic, translational, and clinical research advances to improve anti-tumor efficacy of immunotherapy while minimizing immunotoxicity.
We welcome original research articles and reviews related (but not limited) to:
• Identifying immune biomarkers predicting responses to immunotherapy
• Understanding mechanisms and therapeutic strategies to overcome immunotherapy resistance.
• Revealing mechanisms underlying irAEs in cancer immunotherapy.
• Developing immunotherapeutic approaches to enhance anti-tumor efficacy while abrogating toxicities
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
The goal of this research topic is to broaden our knowledge from translational and basic research works that focus on approaches and ideas to enhance the target specificity of immunotherapeutic reagents and to reduce or prevent adverse events. This will also include the identification of biomarkers to predict responses as well as immunotoxicities.
This Research Topic aims to highlight the ongoing basic, translational, and clinical research advances to improve anti-tumor efficacy of immunotherapy while minimizing immunotoxicity.
We welcome original research articles and reviews related (but not limited) to:
• Identifying immune biomarkers predicting responses to immunotherapy
• Understanding mechanisms and therapeutic strategies to overcome immunotherapy resistance.
• Revealing mechanisms underlying irAEs in cancer immunotherapy.
• Developing immunotherapeutic approaches to enhance anti-tumor efficacy while abrogating toxicities
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Keywords: immunotherapy, resistance to immunotherapy, immune checkpoint inhibitors, immune-related adverse events
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
